Improvement of Glycemic Control, Triglycerides, and HDL Cholesterol Levels With Muraglitazar, a Dual (α/γ) Peroxisome Proliferator–Activated Receptor Activator, in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy

MLA

Michael O’Mahony, et al. “Improvement of Glycemic Control, Triglycerides, and HDL Cholesterol Levels With Muraglitazar, a Dual (α/γ) Peroxisome Proliferator–Activated Receptor Activator, in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy.” Diabetes Care, vol. 29, May 2006, pp. 1016–23. EBSCOhost, https://doi.org/10.2337/dc05-1146.

APA

Michael O’Mahony, Pharis Mohideen, David M. Kendall, Cindy J. Rubin, Jorge Luiz Gross, Jean Marie Ledeine, Paul Norwood, Rene Belder, Ralph A. DeFronzo, Greg Sloan, Kenneth N Sall, Anthony P. Roberts, & Fred T. Fiedorek. (2006). Improvement of Glycemic Control, Triglycerides, and HDL Cholesterol Levels With Muraglitazar, a Dual (α/γ) Peroxisome Proliferator–Activated Receptor Activator, in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy. Diabetes Care, 29, 1016–1023. https://doi.org/10.2337/dc05-1146

Chicago

Michael O’Mahony, Pharis Mohideen, David M. Kendall, Cindy J. Rubin, Jorge Luiz Gross, Jean Marie Ledeine, Paul Norwood, et al. 2006. “Improvement of Glycemic Control, Triglycerides, and HDL Cholesterol Levels With Muraglitazar, a Dual (α/γ) Peroxisome Proliferator–Activated Receptor Activator, in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy.” Diabetes Care 29 (May): 1016–23. doi:10.2337/dc05-1146.